 |
 | |
 |  |
| We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level. |
YMI: YM Biosciences, Inc. (YMI on AMEX; YM on TSX; YMBA on AIM) ymbiosciences.com [Updated as of February 20, 2006.] YMI is a Canadian biotech that has been under the radar but seems to be getting some press lately (see BusinessWeek example, below), and the stock has been reacting accordingly (hovering around the US$3 range until the beginning of 2006; around the US$4.50 to 5.00 range as of mid-February 2006). YMI closed on a US$40 million financing on February 17, 2006 (timed it pretty well @ US$4.25). ymbiosciences.com BusinessWeek article, February 13, 2006 INSIDE WALL STREET YM Biosciences' Cancer Drugs Are Working Another tiny biotech, YM Biosciences (YMI ), trading on the Amex, may also have a winner: Tesmilifene for metastatic breast cancer. Now in Phase III trials, Tesmilifene has been shown to improve the effectiveness of commonly used chemotherapies in prolonging life. In January, YM signed a pact with Sanofi-Aventis (SNY ) to investigate the effect of combining Tesmilifene with Sanofi's Docetaxel to treat fast-growing tumors. The study will test whether using Tesmilifene together with Docetaxel enhances the survival of seriously ill patients without increasing toxicity. Initial research will be conducted in Europe and the U.S. Another YM product, for brain cancer, will go into Phase III trials soon. Mitchell Kaye of XmarkCapital Partners, the lead investor, with 10%, says Tesmilifene could generate annual sales of $1 billion. Now at 3.53 a share, YM could hit 15 in a year, Kaye figures. He also expects good results from trials of YM's AeroLef, an inhaler that provides quick pain relief to cancer victims, to be posted soon. Maher Yaghi of Desjardins Securities, who rates YM a buy, sees it making money in 2009 on projected sales of $36 million, and $43 million in 2010. businessweek.com Tesmilifene and Nimotuzumab are YMI’s two main products. They are described, along with a few others, on YMI’s website. On February 13 2006, YMI announced that Tesmilifene received fast track designation for treatment of metastatic / recurrent breast cancer. Tesmilifene: Tesmilifene is a small molecule which augments the activity of a broad spectrum of chemotherapy agents in a variety of cancers. It has been shown in clinical trials to enhance the activity of anthracyclines and taxanes, as well as cisplatin and 5-FU in a variety of pre-clinical models. In clinical trials there is evidence that tesmilifene increases the cytotoxic effects of mitoxantrone and cyclophosphamide in prostate cancer and doxorubicin, epirubicin and taxol in metastatic breast cancer. In a Phase III study of patients with metastatic breast cancer the addition of tesmilifene to doxorubicin resulted in a 50% increase in survival compared with doxorubicin alone. Tesmilifene has been safely administered to approximately 600 patients in clinical trials. The widespread nature of its activity can be attributed to the fact that it acts at multiple levels in cancer cells… Tesmilifene is currently being developed in trials in breast cancer and prostate cancer, two of the most widespread forms of cancer in North America. Metastatic breast cancer is the second leading cause of cancer-related deaths in North America. Each year, over 100,000 women die from this disease in North America and Europe. Advanced hormone-refractory prostate cancer is the second leading cause of death among men in North America. Each year, almost 100,000 men die from this disease in North America and Europe. The estimated market for tesmilifene in prostate and breast cancer is over US $1 billion world-wide. A successful trial in either or both of the cancers would, by definition, confirm the chemopotentiating nature of tesmilifene and its applicability in combination with a variety of chemotherapeutics (the taxanes, such as paclitaxel and docetaxel, the platins, such as cisplatin, and the anthryacyclines, such as doxorubicin and mitoxantrone) that are used in virtually all solid tumour therapy. ymbiosciences.com Nimotuzumab: A humanized monoclonal antibody (MAb) targeting the Epidermal Growth Factor receptor (EGFr), a key target in the development of cancer therapeutics. EGFr targeting drugs have been shown to improve response when used with conventional treatments such as radiation therapy and chemotherapy… YMB is currently developing nimotuzumab for cancers susceptible to radiation therapy. Radiation therapy is applied in approximately 50% of treatments for solid tumours. The overall market for EGFr inhibitors is estimated at over US $5 billion. There are numerous opportunities for diverse treatment approaches to gain market share, as differences in survival benefits conferred by different products are expected because of varying modes of action. ymbiosciences.com For much more information on YMI, check out the IHUB board, where IO IO has done a much better job digging and summarizing than I could ever do: investorshub.com | ||||||||||||||
|
| Home | Hot | SubjectMarks | PeopleMarks | Keepers | Settings |
| Terms Of Use | Contact Us | Copyright/IP Policy | Privacy Policy | About Us | FAQ | Advertise on SI |
| © 2025 Knight Sac Media. Data provided by Twelve Data, Alpha Vantage, and CityFALCON News |